美国最高法院暂时恢复堕胎药邮寄服务

US Supreme Court lets abortion pill mail delivery restart for now

2026-05-04 14:56:35 UTC / Reuters

By Andrew Chung

May 4, 2026 2:56 PM UTC Updated 24 mins ago

节点运行失败

Boxes of Mifepristone, the first pill in a medical abortion, are seen at Alamo Women’s Clinic in Carbondale, Illinois, U.S., April 9, 2024. REUTERS/Evelyn Hockstein/File Photo Purchase Licensing Rights, opens new tab

• Louisiana challenged abortion pill telemedicine rule
• Federal appeals court backed Louisiana’s challenge
• The Supreme Court’s “administrative stay” lasts for a week

May 4 (Reuters) – The U.S. Supreme Court temporarily reinstated on Monday a federal rule allowing the abortion ​pill to be prescribed through telemedicine and dispensed through the mail, lifting a judicial decision that had blocked the ‌regulation and narrowed access to the medication nationwide.

Justice Samuel Alito issued an interim order pausing a decision by the New Orleans-based 5th U.S. Circuit Court of Appeals to re-impose an older federal rule requiring an in-person clinician visit to receive mifepristone. The 5th Circuit acted in a challenge to the rule ​by the Republican-led state of Louisiana.

The Reuters Iran Briefing newsletter keeps you informed with the latest developments and analysis of the Iran war. Sign up here.

Advertisement · Scroll to continue

The Supreme Court’s action, called an “administrative stay,” gives the justices more time to review emergency ​requests by two manufacturers of mifepristone to ensure that the drug can be provided via telehealth and ⁠the mail while the legal challenge plays out in lower courts.

Alito ordered Louisiana to respond to the drugmakers’ requests by Thursday ​and indicated that the administrative stay would expire on May 11. The court would be expected to extend the interim stay or formally ​decide the requests by that time.

Alito, a member of the court’s 6-3 conservative majority, acted because he is designated by the court to oversee emergency matters that arise in a group of states including Louisiana.

Advertisement · Scroll to continue

The case puts the contentious issue of abortion back in front of the justices, who must confront ​another effort by abortion opponents to scale back access to mifepristone, with the November U.S. congressional elections looming.

The court in 2024 unanimously rejected ​an initial bid by anti-abortion groups and doctors to roll back FDA regulations that had eased access to the drug, ruling that these plaintiffs ‌lacked the ⁠necessary legal standing to pursue the challenge.

Mifepristone, given FDA regulatory approval in 2000, is taken with another drug called misoprostol to perform medication abortions, a method that now accounts for more than 60% of all abortions in the United States.

The ongoing battles over abortion rights follow the court’s 2022 ruling that overturned its 1973 Roe v. Wade precedent that had legalized abortion nationwide. That ruling has prompted 13 ​states to enact near total ​bans on the procedure, while ⁠several others have sharply restricted access.

Louisiana sued the U.S. Food and Drug Administration in 2025 claiming that a rule adopted during Democratic President Joe Biden’s administration in 2023 that eased access to mifepristone ​by eliminating the in-person dispensing requirement is illegal and undermines the state’s near-total abortion ban.

The pill’s ​manufacturer, Danco Laboratories, and ⁠GenBioPro, which makes a generic version, intervened in the litigation to defend the 2023 regulation. Republican President Donald Trump’s administration, citing an ongoing review of safety regulations concerning mifepristone, opposed the state’s challenge.

In April, U.S. Judge David Joseph in Lafayette, Louisiana, declined to block the regulation but agreed ⁠with ​the administration to put the case on hold pending the review. The 5th Circuit blocked the ​rule on May 1.

Reporting by Andrew Chung in New York; Editing by Will Dunham

Our Standards: The Thomson Reuters Trust Principles., opens new tab